Summit Therapeutics (SMMT) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.28), in-line with the analyst estimate of (GBP0.28).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citizens Starts Oaktree Specialty Lending Corp (OCSL) at Market Perform
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Investec Starts Billionbrains Garage Ventures (GROWW:IN) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
